90P HAIC plus sintilimab and bevacizumab biosimilar as treatment for patients with advanced hepatocellular carcinoma (HCC): A phase II trial

Category Primary study
JournalImmuno-Oncology and Technology
Year 2023
This article has no abstract
Epistemonikos ID: 42e4db979008e4edcc49e997eb9eb911b67f2c98
First added on: Feb 17, 2025